Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats

To investigate the effect of the HMG-CoA reductase inhibitor lovastatin on the expression of the receptor for hepatic low-density lipoprotein (LDL) in a rat model with kidney disease, and to identify the mechanisms in statin treatment of nephrotic syndrome with hyperlipidemia, a rat model with nephr...

Full description

Saved in:
Bibliographic Details
Published in:Genetics and molecular research 2014-02, Vol.13 (1), p.938-944
Main Authors: Wei, L X, Chen, L, Wang, W M, Zhang, X H, Wu, J B, Liang, S F, Shu, G Y
Format: Article
Language:English
Subjects:
Animals
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - therapeutic use
Cholesterol, LDL - blood
Disease Models, Animal
Hyperlipidemias - complications
Hyperlipidemias - drug therapy
Liver - drug effects
Liver - metabolism
Liver - pathology
Lovastatin - administration & dosage
Lovastatin - therapeutic use
Male
Nephrotic Syndrome - drug therapy
Nephrotic Syndrome - pathology
Rats
Rats, Sprague-Dawley
Receptors, LDL - genetics
Receptors, LDL - metabolism
Triglycerides - blood
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the effect of the HMG-CoA reductase inhibitor lovastatin on the expression of the receptor for hepatic low-density lipoprotein (LDL) in a rat model with kidney disease, and to identify the mechanisms in statin treatment of nephrotic syndrome with hyperlipidemia, a rat model with nephrotic syndrome was established. Thirty male Sprague-Dawley rats were treated with lovastatin for 2 weeks using gavage. The expression of protein and mRNA of the LDL receptor in the rat liver was detected with Western blot and RT-PCR, respectively, and blood-biochemical indices were also recorded for each group. Compared with the untreated control group, lovastatin treatment significantly decreased the levels of serum total cholesterol, LDL cholesterol, triglycerides, and urinary protein. In addition, lovastatin treatment significantly increased the levels of serum albumin and hepatic LDL receptor proteins, but had no effect on the expression of hepatic LDL receptor mRNA. Treatment with lovastatin markedly increased the expression of the hepatic LDL receptor in rats with nephrotic syndrome, which was accompanied by significantly improved hyperlipidemia.
ISSN:1676-5680
1676-5680
DOI:10.4238/2014.February.19.4